专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050261262A1 Rifamycin derivatives effective against drug-resistant microbes 有权
标题翻译：对抗耐药性微生物有效的利福霉素衍生物
公开(公告)号：US20050261262A1
公开(公告)日：2005-11-24
申请号：US11034195
申请日：2005-01-12
申请人： Zhenkun Ma , Yafei Jin , Jing Li , Charles Ding , Keith Minor , Jamie Longgood , In Kim , Susan Harran , Keith Combrink , Timothy Morris
发明人： Zhenkun Ma , Yafei Jin , Jing Li , Charles Ding , Keith Minor , Jamie Longgood , In Kim , Susan Harran , Keith Combrink , Timothy Morris
IPC分类号： A61K31/33 , A61K31/395 , C07D491/14 , C07D498/08
CPC分类号： C07D498/00
摘要： Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.
摘要翻译：本发明要求具有抗微生物活性的利福霉素衍生物，包括抗药性微生物的活性。本发明的利福霉素衍生物是唯一设计的，因为它们具有通过利福霉素部分的C-3碳与连接基共价连接的利福霉素部分，接头又与治疗部分或抗菌剂/药效基团共价连接。治疗部分可以是喹诺酮，恶唑烷酮，大环内酯，氨基糖苷，四环素核心或与抗菌剂相关的结构/药效团。

2. 发明申请

US20060019986A1 (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions 有权
标题翻译：（R / S）利福霉素衍生物，其制剂和药物组合物
公开(公告)号：US20060019986A1
公开(公告)日：2006-01-26
申请号：US11186425
申请日：2005-07-21
申请人： Charles Ding , Zhenkun Ma , Jing Li , Susan Harran , Yong He , Keith Minor , In Kim , Jamie Longgood , Yafei Jin , Keith Combrink
发明人： Charles Ding , Zhenkun Ma , Jing Li , Susan Harran , Yong He , Keith Minor , In Kim , Jamie Longgood , Yafei Jin , Keith Combrink
IPC分类号： A61K31/4745 , C07D491/14
CPC分类号： C07D401/12 , C07D455/02
摘要： Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or its salts, hydrates or prodrugs thereof; wherein a preferred R1 comprises hydrogen or acetyl and a prefered R2 comprises hydrogen, methyl or other lower alkyls; wherein asterik (*) denotes the carbon bearing the chiral center, wherein absolute configuration is assigned as R or S. Methods of preparation of the aforementioned rifamycin derivatives are also described. The compounds exhibit antimicrobial activities, including activities against drug-resistant microorganisms.
摘要翻译：具有以下通式I结构的利福霉素衍生物（氢醌和对应的醌（C 1 -C 4））形成）：或其盐，水合物或前药; 其中优选的R 1包括氢或乙酰基，优选的R 2 H 2包括氢，甲基或其它低级烷基; 其中asterik（*）表示带有手性中心的碳，其中绝对构型被指定为R或S.还描述了上述利福霉素衍生物的制备方法。这些化合物表现出抗菌活性，包括抵抗耐药微生物的活性。

3. 发明申请

US20060019985A1 Rifamycin derivatives 有权
标题翻译：利福霉素衍生物
公开(公告)号：US20060019985A1
公开(公告)日：2006-01-26
申请号：US11186187
申请日：2005-07-21
申请人： Zhenkun Ma , Jing Li , Susan Harran , Yong He , Keith Minor , In Kim , Charles Ding , Jamie Longgood , Yafei Jin , Keith Combrink
发明人： Zhenkun Ma , Jing Li , Susan Harran , Yong He , Keith Minor , In Kim , Charles Ding , Jamie Longgood , Yafei Jin , Keith Combrink
IPC分类号： A61K31/4745 , C07D491/14
CPC分类号： C07D401/12 , C07D455/02
摘要： Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.
摘要翻译：式I的新型利福霉素衍生物（氢醌和相应的醌（C 1 -C 4））形成）：或其盐，水合物或前药，其中：优选的R 包括氢，乙酰基; L是接头，优选的连接基团元素选自1至5个组的任何组合，如图1所示。 1，其中L不是其中R 1是H，甲基或烷基。本发明化合物显示出有价值的抗生素性质。具有这些化合物的制剂可以用于控制或预防哺乳动物，包括人和非人的感染性疾病。特别地，这些化合物甚至显示出显着的抗菌活性，即使是针对多抗菌菌株的微生物。

4. 发明申请

US20050209210A1 Rifamycin imino derivatives effective against drug-resistant microbes 有权
标题翻译：对抗耐药性微生物有效的利福霉素亚氨基衍生物
公开(公告)号：US20050209210A1
公开(公告)日：2005-09-22
申请号：US11034279
申请日：2005-01-12
申请人： Charles Ding , Yafei Jin , Jamie Longgood , Zhenkun Ma , Jing Li , In Kim , Keith Minor , Susan Harran
发明人： Charles Ding , Yafei Jin , Jamie Longgood , Zhenkun Ma , Jing Li , In Kim , Keith Minor , Susan Harran
IPC分类号： A61K31/4709 , C07D491/14 , C07D498/08 , C07D519/00
CPC分类号： C07D498/08 , C07D519/00
摘要： The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.
摘要翻译：本发明涉及具有抗菌活性的利福霉素3-亚氨基亚甲基（-CH-N-）衍生物，其包括抗药性微生物的活性。所要求的利福霉素衍生物具有通过利莫霉素部分的C-3碳上的亚氨基亚甲基（-CH-N-）基团与连接体共价连接的利福霉素部分，并且连接体又与喹诺酮结构共价连接或其 DNA促旋酶和拓扑异构酶IV抑制剂家族内的药效团。本发明的利福霉素是新颖的，并且表现出抵抗利福平和环丙沙星抗性微生物的活性。

5. 发明申请

US20050203076A1 Rifamycin C-11 oxime derivatives effective against drug-resistant microbes 有权
标题翻译：对抗耐药微生物有效的利福霉素C-11肟衍生物
公开(公告)号：US20050203076A1
公开(公告)日：2005-09-15
申请号：US11076172
申请日：2005-03-09
申请人： Jing Li , Charles Ding , Zhenkun Ma
发明人： Jing Li , Charles Ding , Zhenkun Ma
IPC分类号： A61K31/343 , C07D491/14
CPC分类号： C07D498/08 , A61K31/395 , A61K31/4427 , A61K31/4525 , A61K31/4709 , A61K31/496 , A61K31/5377 , C07D519/00
摘要： The invention relates to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the rifamycin derivatives having an oxime group at the C-11 position.
摘要翻译：本发明涉及具有抗菌活性的利福霉素衍生物，包括抗药性微生物的活性，具体地，在C-11位具有肟基的利福霉素衍生物。

6. 发明授权

US08343944B2 Trisubstituted boron-containing molecules 有权
标题翻译：三取代含硼分子
公开(公告)号：US08343944B2
公开(公告)日：2013-01-01
申请号：US12844748
申请日：2010-07-27
申请人： Yi Xia , Michael Richard Kevin Alley , Yasheen Zhou , Rajeshwar Singh , Charles Ding , Kathy Cao , Jacob J. Plattner , Ligong Ou , Guofeng Jia , Neerja Saraswat , Sreekanth Ramachandran , Ding Zhou
发明人： Yi Xia , Michael Richard Kevin Alley , Yasheen Zhou , Rajeshwar Singh , Charles Ding , Kathy Cao , Jacob J. Plattner , Ligong Ou , Guofeng Jia , Neerja Saraswat , Sreekanth Ramachandran , Ding Zhou
IPC分类号： A61K31/69 , C07F5/04
CPC分类号： C07F5/025 , A61K31/69 , A61K45/06 , A61K2300/00
摘要： This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.
摘要翻译：本发明主要涉及3,4,6-三取代苯并恶唑化合物及其用于治疗细菌感染的用途。

7. 发明申请

US20200175607A1 ELECTRONIC DATA SEGMENTATION SYSTEM 审中-公开
公开(公告)号：US20200175607A1
公开(公告)日：2020-06-04
申请号：US16208155
申请日：2018-12-03
申请人： Charles Ding , Kebin Lu , Thomas Shieh
发明人： Charles Ding , Kebin Lu , Thomas Shieh
IPC分类号： G06Q40/00 , G06F17/10 , G06N7/00
摘要： Segmentation algorithms may operate on vast quantities of data to segment the data into a useful data the model. The segmentation data model may then be applied to additional data that may be received in real time. Further, the real time data may be given a score based on the segmentation model and the desires of the user. The segmentation of the data and the score may be returned to a user and the user may determine if additional actions make logical sense based on the score and segmentation.

8. 发明授权

US08703742B2 Boron-containing small molecules 有权
标题翻译：含硼的小分子
公开(公告)号：US08703742B2
公开(公告)日：2014-04-22
申请号：US13227444
申请日：2011-09-07
申请人： Vincent S. Hernandez , Charles Ding , Jacob J. Plattner , Michael Richard Kevin Alley , Fernando Rock , Suoming Zhang , Eric Easom , Xianfeng Li , Ding Zhou
发明人： Vincent S. Hernandez , Charles Ding , Jacob J. Plattner , Michael Richard Kevin Alley , Fernando Rock , Suoming Zhang , Eric Easom , Xianfeng Li , Ding Zhou
IPC分类号： A61K31/69 , A61P31/04 , A61P31/00 , A61P31/06 , C07F5/02 , C12N9/99
CPC分类号： C07F5/025
摘要： This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
摘要翻译：本发明涉及苯并恶唑化合物及其用于治疗细菌感染的用途。

9. 发明申请

US20070287713A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD 有权
公开(公告)号：US20070287713A1
公开(公告)日：2007-12-13
申请号：US11779319
申请日：2007-07-18
申请人： Peter Cheng , Sean Chen , Pratik Devasthale , Charles Ding , Timothy Herpin , Shung Wu , Hao Zhang , Wei Wang , Xiang-Yang Ye
发明人： Peter Cheng , Sean Chen , Pratik Devasthale , Charles Ding , Timothy Herpin , Shung Wu , Hao Zhang , Wei Wang , Xiang-Yang Ye
IPC分类号： A61K31/41 , A61K31/42 , A61K31/44 , A61K31/445 , A61K31/4965 , A61K31/497 , A61K31/505 , A61P3/10 , C07D239/02 , C07D257/00 , C07D263/30 , C07D271/06 , C07D401/02 , C07D403/02 , C07D413/02
CPC分类号： C07D413/12 , C07D413/14
摘要： wherein Z1 is (CH2)q or C═O; Z2 is (CH2)p or C═O; D is —CH═ or C═O or (CH2)m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; A is (CH2)x where x is 1 to 5, or A is (CH2)x1, where x1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH2)x2—O—(CH2)x3— where x2 is 0 to 5 and x3 is 0 to 5, provided that at least one of x2 and x3 is other than 0; B is a bond or is (CH2)x4 where x4 is 1 to 5; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N, O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4 X5 and X6 is N; and at least one of X2, X3, X4 X5 and X6 is C. R1 is H or alkyl; R2 is H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; R2a, R2b and R2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; and R3, E, Z and Y are as defined herein.

10. 发明申请

US20140324699A1 SYSTEMS AND METHODS FOR LARGE-SCALE TESTING ACTIVITIES DISCOVERY 审中-公开
标题翻译：用于大规模测试活动发现的系统和方法
公开(公告)号：US20140324699A1
公开(公告)日：2014-10-30
申请号：US14263654
申请日：2014-04-28
申请人： Charles Ding , Aoyu Chen , Suyun Xu , Kevin Siegel
发明人： Charles Ding , Aoyu Chen , Suyun Xu , Kevin Siegel
IPC分类号： G06Q20/40
CPC分类号： G06Q20/4016
摘要： Embodiments of the invention relate in part to determining a testing model and providing a testing transaction score for transactions. The testing transaction score may indicate a likelihood that the transaction is a testing transaction. One embodiment of the invention discloses a method comprising receiving a first authorization message for a first transaction using an account, determining a testing transaction score for the first transaction using a testing model, and determining that the first transaction is a testing transaction based on the testing transaction score, wherein the testing transaction score for the first transaction is used for declining a second transaction using the same account conducted after the first transaction.
摘要翻译：本发明的实施例部分地涉及确定测试模型并提供交易的测试交易分数。测试交易分数可能表明交易是测试交易的可能性。本发明的一个实施例公开了一种方法，包括使用帐户接收第一交易的第一授权消息，使用测试模型确定第一交易的测试交易得分，以及基于所述测试确定所述第一交易是测试交易交易分数，其中第一交易的测试交易分数用于使用在第一交易之后进行的相同账户拒绝第二交易。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式